Critical Path Institute

“Jeff jacob and shaun kirkpatrick have a business relationship.”

“Form 990 is prepared by an external cpa firm using information provided by the organization. The form is reviewed by the organization's cfo, president/coo, ceo, the board audit, finance, and risk committee, and the board of directors prior to being finalized.”

“All members of the board of directors and all officers of the organization are required to fill out a conflict of interest form annually. The results are compiled and reviewed by the board's audit, finance, and risk committee. Any actual or perceived conflicts that have the potential to bias any discussions or decisions by the board are discussed by the board. Any director with a real or potential conflict will recuse themselves from any discussion or decision where the conflict has a bearing.”

“A board of directors compensation committee meets and reviews executive compensation annually. Periodically, the committee requests a compensation analysis to determine if employee compensation has remained within market range or if adjustments are required. This information is then used as a basis for the compensation committee's recommendation to the board of directors. An overall salary program for employees must be approved by the board of directors compensation committee before implementation. All employee salary increases must be approved by the president/coo.”

“Articles of incorporation can be found on the arizona corporation commission website. The conflict of interest policy and the financial statements (via the annual report) are posted on the institute's website.”

“Rdca-dap is an fda-funded initiative that will provide a centralized and standardized infrastructure to support and accelerate rare disease characterization with the goal of accelerating therapy development. 2023 proved to be a banner year for the platform. The past year saw 15 disease data sets added to the platform to make it 73 rare disease data sets overall, representing over 34 disease states (15 diseases added in 2023). There are now 445 platform users and 26 active workspaces. Active agreements now include 35 data contribution agreements, eight nord data contribution coversheets and four task force agreements. There were continued advancements in data aggregation and disease modeling in the disease areas of friedreich's ataxia (fa) and progressive supranuclear palsy, as well as the establishment of a clinical trial simulator to inform trial design in fa. This year also marked the release of critical path ontology (cpont) application, which facilitates mapping and linking between different standardized data vocabularies. There was also a significant paper publication, "the future of rare disease drug development: the rare disease cures accelerator data analytics platform (rdca-dap)" in the journal of pharmacokinetics and pharmacodynamics. Another significant publication was that of education modules 1-3. "rare disease drug development: what patients and advocates need to know." rdca-dap made significant contributions to the community in person; the 2023 rare and orphan disease conference had 282 registrants and 202 attendees, including 53 external speakers and panelists across academia, government/regulatory, industry, nonprofits, and patients/caregivers. Lastly, the program made a significant impact on professional development with four webinars held as part of its professional development series, with 760 registrants and 441 attendees.”

“Cure drug repurposing collaboratory (cdrc) was founded in 2020 and is designed to capture real-world clinical outcome data to advance drug repurposing and inform future clinical trials for diseases of high unmet medical need. The past year represented some incredible progress from the collaboratory. Cdrc assisted in the development, consensus, finalization, and deployment of a sarcoma clinical case report form for the cure id app with input from multiple stakeholders, and also initiated a contract with program partner xcures to extract data from sarcoma patient ehrs for pecoma cases. Students from clemson university school of medicine and interns from cdrc also had the opportunity to extract pecoma cases from the literature to cure id, while the program established and led monthly sarcoma workgroup calls for patients, clinicians, and fda oce (oncology centers of excellence) to develop a sarcoma pilot within cure id. Cdrc partnered with hehealth to review and edit the mpox crf on cure id app to promote outreach to patients. The team created an international sti surveillance group under the auspices of who, with existing surveillance efforts in the u.s., canada, and the uk to partner on a project to identify repurposed drugs for neisseria gonorrhea with additional countries as observers. This group helped create the crf for neisseria gonorrhea and organized a monthly long covid clinical think tank call series consisting of 27 clinical trialists regulators, academicians and foundations across the u.s., canada, and europe to review and discuss challenges in setting up and designing clinical trials for this disease.”

“Cp-rnd was founded in september 2022 to lead collaborations that advance treatments to improve the lives of those affected by rare neurodegenerative diseases, including als. Cp-rnd had major highlights in its first full year as a c-path consortium. In regard to its patient-focused drug development process, the group was active in its engagement with people living with diseases, its coordination with accelerating medicine partnership (amp) efforts, and in the formation of a people with lived experiences (pwle) group to give and receive feedback on als-related projects. From a data perspective, cp-rnd reviewed over 70 large databases, with a priority listing created and shared with amp als. The group also summarized results of around 700 studies from clinicaltrials.gov searches. Progress for data dictionary collection and data share agreements remain ongoing. Finally, cp-rnd's scientific contributions are reflected by its efforts to review and collaborate with key opinion leaders regarding nfl/tdp43 and other potential biomarkers for use in als clinical trials.”

“Book/tax difference - operating lease -17,574.”